🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New Review - Elkrief et al - Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies thelancet.com/journals/langa… ERN RARE LIVER Valdig Group #LiverTwitter Rautou Pierre-Emmanuel

1/2 Cholangiocarcinoma is a rare but serious liver cancer😕 🇫🇷 French experts have created guidelines to help doctors diagnose and treat it 🔬 Covers risk factors, screening, diagnosis, and treatment options 🔓 bit.ly/3S6mCzQ #livertwitter

The Lancet Gastroenterology & Hepatology ERN RARE LIVER Valdig Group 📢The "VALDIG PVT criteria" we propose here will help homogenize studies on portal vein thrombosis in patients without and with cirrhosis ✅agreement > 90 % among 57 international experts‼️

Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies Amazing collective work 💪 Everything there is to know, and more! + a new set of imaging criteria to play with ⬇️ thelancet.com/journals/langa… Valdig Group Rautou Pierre-Emmanuel

🚨 A new episode of the Radiology podcast is now available! 🚨 Linda Chu, MD speaks with Dr. Lorenzo Garzelli and Maxime Ronot about Predictors of Intestinal Resection–Free Survival after Endovascular Revascularization #RadPodcasts bit.ly/4f9mrh2

Congratulations to Francesco and team Marco Dioguardi Burgio Maxime Ronot Federica Vernuccio for the article "Discontinuous peripheral enhancement of focal liver lesions on CT and MRI: outside the box of typical cavernous hemangioma" published in Abdominal Radiology 🔗doi.org/10.1007/s00261…

Updated data for atezo + bev vs surveillance in resected or ablated high risk HCC #ESMO24 🔎IMbrave050 👉RFS 33.2 vs 36 mo, HR 0.9 👉OS: HR: 1.26 🧐Benefit not sustained! Disappointing.. 🧐Caveat of (too) early read outs… ESMO - Eur. Oncology #ESMOAmbassadors @ILCA EASL Education

Preoperative mFOLFIRINOX with or without CRT in borderline resectable #PDAC #ESMO24 🔎Phs II trial PANDAS/PRODIGE 44 👉R0 resection 50 vs 55% 👉mOS 32.8 vs 30 mo 👉mOS 35.7 vs 47.9 mo (resected) 🧐no benefit in R0 rate or OS for CRT 🧐 mFOLFIRINOX with favorable OS

The position paper from EASL about "management of rare primary liver cancers" was recently published in Journal Of Hepatology EASLnews Journal of Hepatology Claudia Campani Jessica Zucman-Rossi Maria Reig journal-of-hepatology.eu/article/S0168-…

🔥off the press Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC JHEP Reports 🔎🗺️RWD study ❓how to best select for TACE > AFP & Tumor burden 🧐helpful for the discussion in the tumor board 👇my author link: doi.org/10.1016/j.jhep… ESMO - Eur. Oncology

💥EXPERT OPINION Integration of new technologies in the multidisciplinary approach to primary liver tumours ➡️The next-generation tumour board Full text here👉journal-of-hepatology.eu/article/S0168-… @Naultjc #LiverTwitter

Read 'open access' at bit.ly/3AdVol6 "Early-Life Infections, Antibiotics and Later Risk of Childhood and Early Adult-Onset Inflammatory Bowel Disease: Pooled Analysis of Two Scandinavian Birth Cohorts" by Mårild et al #GItwitter #IBD

Risk of HCC in Subcentimeter Liver Nodules Identified on Surveillance Ultrasound CGH doi.org/10.1016/j.cgh.… 🔎 Systematic Review, 9 studies, 888 pts 👉risk of HCC: 21.3% 👉risk factors: older age, male sex, elevated AFP, low plts, CP B 🧐repeat ultrasound in 3-6 mo

🩺MRI-assessed intratumoral fat was generally nonprognostic; however, homogeneous intratumoral fat correlated with longer recurrence-free and overall survival in an Asian cohort of hepatocellular carcinoma patients. Findings from Maxime Ronot! pubs.rsna.org/doi/10.1148/ra…

Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment - The Lancet Oncology thelancet.com/journals/lanon…

❕Patient and physician expectations regarding disease and treatment of advanced HCC: The prospective PERCEPTION1 study 🔓#OpenAccess at👉jhep-reports.eu/article/S2589-… #LiverTwitter #HCC Jean-Charles Nault

🔥off the press: Tumor burden with AFP improves survival prediction for TACE treated patients with HCC JHEP Reports doi.org/10.1016/j.jhep… 🔎 International observational study 👉Easy to use tool to predict outcome ESMO - Eur. Oncology EASL Education ILCA

🆕EASL Clinical Practice Guidelines on the management of #hepatocellularcarcinoma❗️ ✅Updated advice for managing patients with #HCC & comprehensive review of pertinent data Full text👉bit.ly/3VKZmcy #CPGs #LiverTwitter EASLnews EASL Education Aleksander Krag

🚨EASL CPG on the management of HCC in Journal of Hepatology Major update! ✅ LI-RADS endorsed ✅ Refined treatment algo ✅ More evidence supporting locoregional treatments ✅ Up-to-date discussions 👉bit.ly/3VKZmcy

Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy | Targeted and Immune Therapy | JAMA Oncology | JAMA Network jamanetwork.com/journals/jamao…